Overview

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.
Treatments:
Decitabine